TargetTyrosine-protein kinase Tec(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Tec(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Tec(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Tec(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Tec(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Tec(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Tec(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 550nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ITK/TSK(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ITK/TSK(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ITK/TSK(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ITK/TSK(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ITK/TSK(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ITK/TSK(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase ITK/TSK(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Suzhou Baijibugong Pharmaceutical Technology
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The following Table shows the activity of selected compounds of this invention in the BTK, TEC, BLK, LYN, LCK inhibition assay. More data for this Ligand-Target Pair